RxDoctor Payments Data

Kelly Moore, NP

Psychiatric/Mental Health · Boise, IDNPI 1104303072

Payments from drug & device makers

$805in general payments, 2019–2025

Across 26 payments — averaging $30.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$255
  • AbbVie$138
  • Teva Pharmaceuticals USA, Inc.$106
  • Neurocrine Biosciences, Inc.$76
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$72
  • Axsome Therapeutics, Inc.$64
  • plus $94 from 4 others

What the payments were for

  • Food & beverage$805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$805 in reported general payments places this provider in the 55th percentile of 221 psychiatric/mental health providers in Idaho.

See all psychiatric/mental health providers in Idaho

Medicare billing

Part B allowed, 2024
$7,339
Medicare patients
20
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl14$19,781
Ramelteon14$2,674
Lisdexamfetamine Dimesylate15$2,442
Aripiprazole21$2,369
Vilazodone Hcl15$1,064
Prazosin Hcl35$908
Desvenlafaxine Succinate ErDesvenlafaxine Succinate21$867
Lamotrigine47$805
Trazodone Hcl83$790
Duloxetine Hcl44$624
Bupropion XlBupropion Hcl34$492
Gabapentin31$485
Venlafaxine Hcl ErVenlafaxine Hcl32$477
Buspirone Hcl23$474
Quetiapine Fumarate ErQuetiapine Fumarate14$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$138$19,78114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 221 psychiatric/mental health providers in Idaho.

Other psychiatric/mental health in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →